Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be at a significantly lower risk of dementia. The researchers compared the health outcomes of more than 110,

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By encouraging the kidneys to eliminate sugar from the body through urine, they reduce blood sugar.